Denali Therapeutics Inc
Price
FilingsNewest: 10-Q, Quarterly reportAug 6 →InsidersNo open-market buys. 4 insiders sold $1.3M, 3 of 7 sales on a 10b5-1 plan.→HoldersBlackRock 8.8%Baillie Gifford & 7.5%State Street 4.4%→PeersClosest companies: ALEC, PASG, DYN→
From the filings
Figures
- Revenue
- $0.00last 12 months
- Net income
- −$511.5Mlast 12 months
- Operating cash flow
- −$412.3Mlast 12 months
- Cash and equivalents
- $201.5Mat the last balance sheet
- Shares outstanding
- 159.8M shareson issue